Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anything under 0.10 was Gift here way under valued...
Upward trend continues. Closing in on .12 this morning
Medical Cannabis Stocks (SKYE)
Medical cannabis is a type of therapy prescribed by doctors for health conditions and symptoms. This means patients can only access cannabis treatments with a prescription from their doctors. To date, the drug has been used to treat Alzheimer's, different forms of cancer, various mental health conditions, multiple sclerosis, nausea, and pain.
The industry has been moving forward since California became the first state to legalize medical pot in 1996. Research conducted in 2018 stated that Sanofi Aventis (SNY) and Merck (MRK) are among the top cannabis-related patent holders.1? Companies involved in the use of marijuana for medical uses are GW Pharmaceuticals (GWPH), Tilray (TLRY), Corbus Pharmaceuticals (CRBP), Cara Therapeutics (CARA), and Zynerba Pharmaceuticals (ZYNE).
source: Investopedia
Cannabis CEO Says Marijuana legalization within 2 years... https://www.cnbc.com/2021/01/27/tilray-ceo-expects-us-federal-cannabis-legalization-within-two-years.html
Congress working on Marijuana legislation..Good things are coming in Cannabis.. https://www.marijuanamoment.net/chuck-schumer-says-marijuana-reform-bills-are-being-merged-as-congress-moves-to-legalize/
I am hanging in there for a $1, or even a fourth of that. I guess I need to go ahead and dump in another 10k at this point.
patented mj eye therapy...$1...incoming. $SKYE
no shares under .068....accumulated $SKYE
I can't tell from where I am sitting.
Skye Bioscience, Inc., formerly Emerald Bioscience, Inc., is a biopharmaceutical company, which is engaged in engineering cannabinoid derivatives to treat glaucoma and other diseases. The Company is focused on discovery, development, and commercialization of cannabinoid-derived therapeutics, with clinical and commercial differentiation for the treatment of glaucoma diseases. Its programs include THCVHS and CBDVHS. The Company's lead candidate, THCVHS, a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). It chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. CBDVHS is a prodrug of cannabidiol (CBD) that has demonstrated biological activity in prodrug form (CBDVHS) and as native (natural) CBD. The Company has chemically-modified the CBD molecule to improve on its known positive effects.
Emerald Bioscience Creates Unique Path to Prevent Blindness Using Patented Synthetic Cannabinoids
10:17 pm ET December 4, 2020 (Benzinga) Print
The rapid innovation and growth in biotechnology is being used to define, validate, and enhance therapeutic outcomes from cannabinoids. The results could prove highly valuable to patients, as well as the pharmaceutical sector and its investors.
That is according to Punit Dhillon, the recently appointed CEO at Emerald Bioscience Inc (OTC: EMBI), a San Diego-based biotech focused on cannabinoid-derived therapies for a spectrum of diseases with unmet medical needs. Through his various leadership roles at biopharmaceutical companies like OncoSec Medical Inc (NASDAQ: ONCS) and Inovio Pharmaceuticals Inc (NASDAQ: INO), Dhillon learned first-hand what it takes for biotech businesses to catalyze growth and provide well-differentiated approaches for the treatment of diseases.
Dhillon spoke with Benzinga about Emerald's proprietary technology which substantially enhances the local delivery, bioavailability, dosing, and – most importantly – potentially advantageous therapeutic effects of cannabinoids for diseases like glaucoma.
A First In Medicine: THC and CBD – the two major cannabinoids which act on specific receptors found on the endocannabinoid system – have been shown to maintain homeostasis in the body. Emerald’s research and development has further pushed the boundaries, bringing new ways to effect change on the endocannabinoid’s signalling pathways that involve a whole range of different physiological and pathological conditions.
“The endocannabinoid system is becoming increasingly recognized as an important system in the body that can be pharmacologically targeted for therapeutic benefits related to a myriad of diseases involving inflammation, pain, neurodegeneration, and immune modulation, to name a few."
Since Dhillon’s arrival, the firm has clarified a development path for its lead molecule.
"We're focusing our initial efforts on ocular opportunities, where there's been very little innovation, broadly speaking," the CEO said in reference to Emerald's clinical study of cannabis-infused treatments for glaucoma, the increase in intraocular pressure (IOP) that damages the retinal ganglion cells connected to the optic nerve, and causes irreversible loss of vision.
Using THC as medicine alone does have drawbacks, however. Specifically, THC is not concentrated enough to lower IOP. Additionally, the appearance of being under the influence and persistently low blood pressure are two other key detractors.
Emerald’s active pharmaceutical ingredients (API) overcome these common issues by enabling local delivery of more hydrophilic, comparatively minuscule THC doses directly to the eye, as an eyedrop. The drug's solubility offers deeper penetration into the eye where the THC conversion then delivers the molecule to the specific organ that regulates IOP.
“In our planned clinical study in humans, we are in fact going to have the benefit of using an agent that has already shown utility in humans – but our version has the basis to be very safe and far more effective."
“By controlling IOP, we can slow and preserve vision loss,” the CEO added. “Our mechanism is very unique compared to what exists. We’ve been able to deliver this and have an improvement over standard drugs.”
One Big Thing: There is a large subset of patients in the world who develop vision loss even while having controlled or normal IOP levels.
“The exact reason why these patients still suffer damage to their optic nerve and vision loss is not completely understood, but neurodegeneration is evident. Existing drugs offer no benefit for these patients," said Dhillon.
This area, according to the CEO, is where Emerald may inflict game-changing results.
“There is significant peer-reviewed literature to support the ability of cannabinoids, specifically THC, to provide neuroprotection of these cells that make up the optic nerve. There is nothing currently in the market that provides this neuroprotective benefit, making our mechanism very unique compared to what exists."
Path To Viability: Presently, Emerald’s work alongside a university that has a long-standing relationship at the federal level has given it a leg up in securing compelling proprietary technology.
"The University of Mississippi was given the first and only federal license to grow and conduct research on cannabis by the DEA going back 50 years. Their research produced the THCVHS and CBDVHS molecules that Emerald subsequently licensed from them," Dhillon said in reference to Emerald's fast-paced research and development.
Emerald’s products won’t be found at the storefront cannabis shop. Instead, the firm applies the full knowledge and capability of decades of R&D, clinical, and business development experience in the life sciences industry to advance differentiated, patented molecules through regulated processes, to validate their medical capabilities fully.
“The wider the "moat" of strong intellectual property and the stronger the data generated in well-designed clinical studies, the greater the potential interest a company with new medicines can generate from professional biotech investors and prospective pharmaceutical partners.”
Growth Prospects: Going forward, Emerald will look to do more preclinical assessments comparing its lead THCVHS compound to existing commercialized glaucoma drugs over their ability to reduce IOP and provide neuroprotection of the optic nerve.
If the firm can demonstrate superior IOP lowering and neuroprotection, then it's painting a new precedent for the treatment of glaucoma and potentially other diseases.
"We aim to start our first human study in the third quarter of 2021,” Dhillon added.
“Because of the nature of this disease – our monitoring period for each patient will be measured in just weeks – the overall study will be fast and relatively low-cost, and the study is designed in a manner that will also provide an early indication of efficacy not normally available in typical phase 1 studies.”
On another note, Emerald is moving forward on a rebranding process to represent the change in leadership and reinvigorated focus to enter the clinic within the next nine months. As part of this initiative, there will be a change to the firm’s corporate name and trading symbol, which is expected to occur in January.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Thanks for posting... added another 10k today
It's definitely time for something.
Are we going to see the old .03-.04 price return?
I think it needs a bit more comunication regarding the name change and future. Proberbly scared a few people. Dealing with scientists...the are not known for these kind of skills.
It surprised me the wrong way today.
Should of sold it yesterday like I normally would have and bought back in today.
What is SKYE going to do going forward?
Marijuana Reform positive for (SKYE)...
The first marijuana reform bill of the new Congress was introduced this week. It’s not the comprehensive legalization legislation that advocates are waiting for, but it would reschedule cannabis under federal law..
Reclassification would also make scientific research easier, since cannabis’s current Schedule I status creates additional hurdles for studies..
https://www.marijuanamoment.net/congressman-files-first-federal-marijuana-reform-bill-of-2021/
Definitely headed the wrong way today.
You care to elaborate?
This one, will surprise everyone.
This will go to 1$ soon after pr.
I wonder why company held stock went from 17.54% to ZERO.
Any ideas?
Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience
Tue, January 19, 2021, 8:30 AM
Name change reflects Company’s evolution, renewed team and strategic focus on advancing its lead compound into human trials Company to trade under ticker SKYE effective January 19, 2021
San Diego, Calif, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has changed its name from Emerald Bioscience, Inc. to Skye Bioscience, Inc. The Company will trade under its new ticker symbol, “SKYE,” on the OTC effective at market open on Tuesday, January 19, 2021. The new website for Skye Bioscience is www.skyebioscience.com.
“Over the past few months, we have reinvigorated our business with a new team and strong commitment to advance the clinical development plan for our promising drug candidate to treat glaucoma. Our new name, Skye Bioscience, reflects this transformation and the Company's vision and conviction in its technology and its potential impact on human health," said Punit Dhillon, CEO of Skye Bioscience.
"Since September, our Company has made significant progress on its development plan for its lead molecule, THCVHS, with important steps taken to finalize the formulation and manufacture of this drug. With manufactured drug expected in the near term, we plan to conduct additional important preclinical studies to further validate intraocular-pressure-lowering activity as well as the potential neuroprotective benefits of our drug. With other IND-enabling preclinical work in motion, we are also well on our way toward our first clinical trial planned to start in the third quarter of this year and provide data readouts in Q2 2022. These milestones represent a compelling set of outcomes that we believe can be impactful for the company.
One of Skye’s planned preclinical studies will compare the intraocular-pressure-lowering capability of THCVHS against, and in combination with, two other market-leading glaucoma drugs. Another will provide an initial assessment of THCVHS’ ability to provide neuroprotection, a capability that today is unavailable with current therapies. A neuroprotective drug could potentially help millions of patients from going blind, a significant and unfortunate outcome of glaucoma.
With the final preclinical steps planned, clinical sites identified, and protocols and timelines established, Skye is on a relatively short path to initiate its first clinical trial in Q3 2021. This first-in-human Phase 1 study of its lead therapeutic candidate, THCVHS, to treat glaucoma will assess the safety and tolerability of single and multiple ascending doses. The study design will also provide an initial assessment of its impact on intraocular pressure (IOP) in healthy patients with normal IOP as well as in a subset of patients with glaucoma and/or elevated IOP.
"Our confidence in the potential of THCVHS as a treatment for glaucoma is rooted in the multiple peer-reviewed clinical studies demonstrating the effectiveness of THC in lowering IOP. These prior studies, however, also demonstrated unwanted adverse effects of THC when administered systemically through ingestion or inhalation. Through rational drug design and bioengineering, THCVHS was created to be delivered safely and effectively delivered directly into the eye in order to leverage its inherent capabilities to address important health issues of the eye. We believe our unique, fully patented drug can avoid the adverse systemic effects of THC while providing superior IOP-lowering activity to help protect and preserve vision. As we move forward in 2021, we look forward to advancing our clinical objectives expeditiously and leveraging the compelling opportunities ahead of us," said Mr. Dhillon.
Existing shareholders interested in getting an updated statement representing book shares or a revised stock certificate can email Skye’s transfer agent, ClearTrust, LLC, at inbox@cleartrusttransfer.com.
Weare going up, from here...
Weird that they changed the name again so soon. I guess "Emerald" was no good? Is emerald still a brand of cannabis company in canada?
Emerald Bioscience Inc., EMBI, changed to Skye Bioscience Inc., SKYE:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Lovely turn of events. :)
INDEED I DID! I WAS HOPING FOR A QUICK FLIP ON THE .03 SHARES. MAYBE 50%. WASNT EXPECTING THIS.
But u said they were going bankrupt.
Awesome day. Glad I reduced my average PPS when it fell to .03
Too high too fast.. maybe .04 won't happen but a trade to .06 seems reasonable
I'm out. Made my flip. Looking to re-enter around .04
EMBI has 11 institutional Owners: https://fintel.io/so/us/embi
(SABBY MANGEMENT HOLDINGS) OWNERSHIP-EMBI LEGIT.. SABBY ASSETS VALUE $ 669,857,000 USD
Most recent portfolio value is calculated to be $ 669,857,000 USD. Actual Assets UnderManagement (AUM) is this value plus cash (which is not disclosed). Sabby Management, Llc's topholdings are Biogen Inc. (US:BIIB) , Biogen Inc... https://fintel.io/so/us/embi/sabby-management-llc / Good Enough for SABBY good enough for me..
Sabby Management, Llc discloses 5.79% ownership in EMBI / Emerald Bioscience,. Inc.2021-01-07 - Sabby Management, Llc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 14,480,000 shares of Emerald Bioscience, Inc. (US:EMBI). This represents 5.79 percent ownership of the company. In their previous filing dated 2020-07-31, Sabby Management, Llc had reported owning 15,000,000 shares, indicating a decrease of -3.47 percent.. https://fintel.io/so/us/embi/sabby-management-llc
Sabby - 14 million shares. He took IBIO from .06 to $8. Load heavy here.
You should try the world wide web. It has a lot of information.
Could you elaborate? Where can I find more info?
An infamous institutional investor.
Did anyone see the KCSA presentation on 1/7? Is there a replay somewhere? Thanks.
sabby is here because they think 10x is possible and that they can steal many shares cheap along the way...
It's the Authorized Shares Not the Float... But I'll be honest I don't like it.. 5 billion sounds like we're headed for dilution...Me personally I believe the trading range Emerald is in is the bottom.. So I'm not too concerned but when it runs up I'm out..
Followers
|
138
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6315
|
Created
|
11/12/14
|
Type
|
Free
|
Moderators |
Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).
Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.
One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.
At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.
According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.
Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.
In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.
Additionally, it has been demonstrated:
We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.
Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.
Science First
The foundation of Skye Bioscience.
Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.
Product-led
Commercial differentiated applications to provide therapeutic benefits.
Impact driven
Change makers. Platform solutions that can extend beyond a single disease.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.
Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.
Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.
Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.
Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development.
Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.
Dr. Pasquale is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation ..
Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.
Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.
Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |